150779-71-8
| 中文名称 | 150779-71-8 |
|---|---|
| 中文同义词 | 化合物 T16866;化合物 SDZ281-977 |
| 英文名称 | SDZ 281 977 |
| 英文同义词 | SDZ 281 977;SDZ-LAP 977;Benzoic acid, 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxy-, methyl ester;SDZ281 977,SDZ-281-977,SDZ281977;Methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate |
| CAS号 | 150779-71-8 |
| 分子式 | C18H20O5 |
| 分子量 | 316.35 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 150779-71-8.mol |
| 结构式 |  |
150779-71-8 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells) and MDA-MB-231 (breast carcinoma cells). These cell lines are selected because of their sensitivity for SDZ 281-977. The IC 50 values for inhibition of growth of A431, MIA PaCa-2 and MDA-MB-231 cells are 0.21 μM, 0.29 μM and 0.43 μM, respectively.
Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-101756 | SDZ281-977 | 150779-71-8 | 1 mg | 1363元 |
| 2025/12/22 | HY-101756 | SDZ281-977 | 150779-71-8 | 5 mg | 3000元 |